Nicola Pozzi: A Brand-New Mechanism to Reduce Thrombosis Without Increasing Bleeding Risk
Nicola Pozzi, Associate Professor of Thrombosis and Hemostasis and Autoimmunity at Saint Louis University School of Medicine, shared a post on LinkedIn about a recent article he and his collegues co-authored, adding:
“From structure, to function, to proof-of-concept therapeutic.
A brand-new mechanism to reduce thrombus formation without increasing bleeding risk inspired by our research on Antiphospholipid Syndrome (APS).
Extremely proud of this work, how it has evolved over the years and the incredible people involved (Marisa Brake, Suresh Kumar, Catherine Lapointe, Glenn Merrill-Skoloff, Sol Schulman, Matthew Flick, and Robert Flaumenhaft at Harvard Medical School, Saint Louis University School of Medicine and Blood Research Center at UNC)
We believe this approach has great potential, and we’re excited to moving it forward.
Also, here’s an interesting research question.
Are all autoantibodies bad?
Early to say but maybe not all of them are…”
Title: In vivo targeting of open prothrombin with the monoclonal antibody POmAb results in anticoagulation without excessive bleeding
Authors: Marisa A Brake, Suresh Kumar, Catherine Lapointe, Glenn Merrill-Skoloff, Sol Schulman, Matthew J Flick, Robert Flaumenhaft, Nicola Pozzi
Read the Full Article on JTH
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 17:21Emmanuel J Favaloro: Acquired Hemostasis Disorders Featured in New Issue of Seminars in Thrombosis and Hemostasis
-
Mar 13, 2026, 17:17Paolo Zamboni: New Insights from Australia on Jugular and Azygous Vein Chronic Obstruction
-
Mar 13, 2026, 17:06Srishti Goyal: Can Thalassemia Major Be Prevented?
-
Mar 13, 2026, 16:59Tagreed Alkaltham: Preventing the Risk of Transfusion Reactions Before They Occur
-
Mar 13, 2026, 16:52Giuseppe Lippi: New Insights Into Antiphospholipid Antibodies and Cardiovascular Thrombosis
-
Mar 13, 2026, 16:51Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
-
Mar 13, 2026, 16:47Sinju Thomas: Combined Red Cell and Plasma Exchange for Severe FES in Sickle Cell Disease
-
Mar 13, 2026, 16:44Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
-
Mar 13, 2026, 16:36Muhammad Bilal: Principles and Clinical Uses of the Coombs Test